Faculty Directory

Adam Friedman

Adam Friedman

Interim Chair, Department of Dermatology
Professor of Dermatology

Office Phone: 202-741-2600
Email: Email
Department: Dermatology


  • BA, University of Pennsylvania, 2002
  • MD, Albert Einstein College of Medicine, 2006


Adam Friedman, MD, FAAD is an Associate Professor of Dermatology and serves as Residency Program Director, Director of Translational Research, and Director of t in the Department of Dermatology at The George Washington University School of Medicine & Health Sciences and George Washington Medical Faculty Associates. Dr. Friedman completed his undergraduate training at the University of Pennsylvania and graduated with Distinction in Dermatologic Research at the Albert Einstein College of Medicine in New York. He completed his internship at New York Hospital Queens, and returned to Einstein for his Dermatology residency and was appointed Chief Resident during his final year. Dr. Friedman joined the Einstein faculty after graduation from 2010-2015, during which time he was the Director of Dermatologic Research, Director of the Translational Research Fellowship, and the Associate Program Director.

Dr. Friedman’s clinical interests span the gamut of medical and pediatric dermatology, including acne, eczema, psoriasis, skin infections, hair loss, wound healing, urticaria, blistering diseases, lupus, sarcoidosis, and skin cancer to name a few. Dr. Friedman lectures extensively in both national and international forums, and serves on a myriad of committees and advisory boards. He is a dermatology expert for healthguru.com and everydayhealth.com, and hosts an online series titled “Ask an Expert.” 

Dr. Friedman is also committed to resident and medical education. He currently serves on the AAD Sulzberger Committee on Education as well as the Poster Task Force, and is the Senior Editor of the Dermatology In-Review Online Workshop and Director of the Oakstone Institute Dermatology Board Review. Dr. Friedman served as the Chair of the Dermatology Section of the New York Academy of Medicine and now as Vice Chair, and in line with his research interests, as the Vice President of the Nanodermatology Society. 


  1. Collagen Powder vs Primary Closure for 3 mm Punch Biopsy Wound Healing: A Pilot Study
    1. CPN
    2. 11/2017-11/2018
    3. Total funds: $35,000
    4. Role: PI
  2. Longitudinal Trial to Understand Symptomatology in Prurigo Nodularis (Chronic Prurigo)
    1. Kiniksa
    2. 7/2017-7/2018
    3. Total funds: $42,931
    4. Role: PI
  3. A-101 vs. Cryotherapy: An ex-vivo determination of melanocyte toxicity
    1. Aclaris
    2. 4/2017 – 11/2017,
    3. Total funds: $67, 411
    4. Role: PI
  4. Evaluating the biological impact of Bensal HP on wound healing
    1. Valeant Pharmaceuticals
    2. 7/2014 – 4/2017, $63,862
    3. Role: PI
  5. Enhanced wound healing using topically administered nanoparticle-encapsulated siRNA
    1. Women’s Dermatologic Society
    2. 4/2014-4/2015
    3. Total funds: $10,000
    4. Role: PI
  6. Curcumin Nanoparticles as an Innovative, Multi-mechanistic Antimicrobial and Wound Healing Accelerant”
    1. Feldstein Medical Foundation
    2. 4/2014-4/2015
    3. Total funds: $60,000
    4. Role: PI
  7. Sanguinarine nanoparticles for targeted melanoma therapy in vitro
    1. American Skin Association Medical Student Grant Targeting Skin Cancer
    2. 4/2014-4/2015
    3. Total funds: $7,000
    4. Role: PI
  8. Efficacy of personal protective equipment (PPE) in preventing dermal and inhalation exposure to nanoparticles and nanoagglomerates (Phase III)
    1. NIOSH
    2. 6/2013 – 6/2014
    3. Total funds: $175,000
    4. Role: Co-PI
  9. Identifying new biological targets of hypochlorous acid in Atopic Dermatitis: A histologic analysis
    1. Onset Therapuetics
    2. 5/2013 – 4/2014
    3. Total funds: $28,850
    4. Role: PI
  10. Enhanced wound healing using topically administered nanoparticle-encapsulated siRNA
    1. Department of Defense/TATRC
    2. 06/2012 - 07/13
    3. Total funds:$349,856
    4. Role: Co-PI  
  11. Antimicrobial and Wound Healing Impact of Nitric Oxide Releasing Nanoparticles
    1. Janssen
    2. 7/2011 – 6/2014
    3. Total funds: $41,500 yearly
    4. Role: PI
  12. Antimicrobial and Wound Healing Impact of Nitric Oxide Releasing Nanoparticles
    1. Dermatology Foundation Career Development Award Program
    2.  7/2011 – 6/2012, 7/2012-6/2013, 7/2013-6/2014
    3. Total funds: $55,000 
    4. Role: PI
  13. Antimicrobial and Wound Healing Impact of Nitric Oxide Releasing Nanoparticles
    1. Dermatology Foundation Dermatologist Investigator Research Fellowship
    2. 7/2010-6/2011
    3. Total funds: $30,000
    4. Role: Fellow; PI Joshua Nosanchuk
  14. Antimicrobial and Wound Healing Impact of Nitric Oxide Releasing Nanoparticles
    1. La Roche-Posay North American Foundation Award Program
    2. 4/2009-3/2010
    3. Total funds:$10,000
    4. Role: PI
  15. Antimicrobial and Wound Healing Impact of Nitric Oxide Releasing Nanoparticles
    1. Women’s Dermatologic Society
    2. 7/2009-6/2010
    3. Total funds: $8,000
    4. Role: PI
  16. Antimicrobial and Wound Healing Impact of Nitric Oxide Releasing Nanoparticles
    1. American Society of Dermatologic Surgery Cutting Edge Research Grant Award
    2. 10/2009-9/2010
    3. Total funds: $15,000


Annual Michael Fisher Lectureship, Albert Einstein College of Medicine, 2018
Innovations in Resident Training, Journal of Drugs in Dermatology, 2018
Washingtonian Top Doctor 2017
Elle 2017 Beauty Genius Award
Teacher of the Year, Department of Dermatology, George Washington School of Medicine and Health Sciences, 2015-2016
John R. Pearson Named Lectureship, Department of Dermatology , University of Massachusetts Medical School,  2016
New York Academy of Medicine Fellow Ambassadorship Program, 2015
Special Recognition Award, Division of Dermatology, Montefiore - Albert Einstein College of Medicine, 2015
American Academy of Dermatology Annual Meeting Poster Task Force Award – First Place, 2015
Nanoscience Research Leaders Award, 2015
American Dermatologic Association Young Leader Award, 2014
Vitals.com Compassionate Physician Award 2014
Superdoctors NY Rising Star Award 2013-2015

Feldstein Foundation Medical Research Award, 2014
JDD Leaders of Distinction Award, 2014
Journal of the American Academy of Dermatology Editorial Mentorship Program, 2013
American Academy of Dermatology Academic Leadership Program, 2012
Dermatology Foundation Career Development Award, 2011, 2012, 2013
Leo M. Davidoff Award for Outstanding Achievement in the Teaching of Medical Students, 2010
Dermatology Foundation Dermatologist Investigator Research Fellowship, 2010
MMC Young Investigators Symposium Award, 2010
ARTE Scholar Poster Competition Award, 2010
Cosmetic Surgery Forum Travel Scholarship, 2009
American Society for Dermatologic Surgery Resident Scholarship Award, 2009
Chief Academy, 2009
American Academy of Dermatology Everett C. Fox, MD Award, 2009  - First Place
La Roche-Posay North American Foundation Award, 2009 – First Place
Women’s Dermatologic Society Academic Research Grant, 2009
MMC Young Investigators Symposium, Parviz Lalezari Award for Research Excellence, 2009
CSCR/MWAFMR Trainee Travel Award, 2009
American Society of Dermatologic Surgery Cutting Edge Research Grant Award, 2008


Dr. Friedman is currently investigating novel nanotechnologies that allow for controlled and sustained delivery of a wide spectrum of physiologically and medicinally relevant molecules, with an emphasis on treating infectious diseases, accelerating wound healing, immune modulation, and correcting vascular dysfunction. He holds several patents derived from these investigations, and has published over 150 papers/chapters and 2 textbooks on both his research as well as a variety of clinical areas in dermatology with an emphasis on emerging medical therapies. He has received awards from multiple organizations such as the American Dermatologic Association, American Academy of Dermatology, American Society for Dermatologic Surgery, Journal of Drugs in Dermatology and the La Roche Posay North American Foundation.

Examples of recent publicartions include:

  1. Landriscina A, Rosen J, Blecher-Paz K, Long L, Ghannoum M, Nosanchuk J, Friedman AJ. Nitric oxide-releasing nanoparticles as a treatment for cutaneous dermatophyte infections. Sci Lett 2015, 4: 193
  2. Landriscina A, Rosen J, Albanese J, Amin B, Friedman A. Identifying New Biologic Targets in Atopic Dermatitis: A Retrospective Histologic Analysis. J Am Acad Dermatol.  2015 Jul 10. pii: S0190-9622(15)01815-0.
  3. Qin M, Landriscina A, Rosen J, Wei G, Kao S, Olcott W, Agak GW, Paz KB, Bonventre J, Clendaniel A, Harper S, Adler B, Krausz A, Friedman J, Nosanchuk J, Kim J, Friedman AJ. Nitric Oxide Releasing Nanoparticles Prevent Propionibacterium acnes Induced Inflammation by both Clearing the Organism and Inhibiting Microbial Stimulation of the Innate Immune Response. J Invest Dermatol. 2015 Jul 14.
  4. del Pilar Sosa Peña M, Gottipati A, Tahiliani S, Neu-Baker NM, Fram MD, Friedman AJ, Brenner S. Hyperspectral imaging of nanoparticles in biological samples: simultaneous visualization and elemental identification. Microsc Res Tech. 2016;79(5):349-58.
  5. Krueger JG, Kircik L, Hougeir F, Friedman A, You X, Lucas N, Greenberg SJ, Sweetser M, Castro-Borrero W, McCroskery P, Elkins J. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther. 2016;33(7):1231-45
  6. Doerner J, Chalmers SA, Friedman A, Putterman C. Fn14 deficiency protects lupus-prone mice from histological lupus erythematosus-like skin inflammation induced by ultraviolet light. Exp Dermatol. 2016;25(12):969-976
  7. Yadgar RJ, Bhatia N, Friedman A. Cutaneous fungal infections are commonly misdiagnosed: A survey-based study. J Am Acad Dermatol. 2016 Nov 11
  8. Idelchik MPS, Neu-Baker NM, Chandrasekaran A, Friedman AJ, Frame MD, Brenner SA. Relative Quantitation of Metal oxide nanoparticles in a cutaneous exposure model using enhanced darkfield microscopy and hyperspectral mapping. NanoImpact. 2016; 3-4: 12-21.
  9. Martinez L, Mihu M, Cabral V, Pattabhi R, Tar M, Davies K, Friedman A, and Nosanchuk J. Sustained Nitric Oxide-Releasing Nanoparticles Interfere with Methicillin-Resistant Staphylococcus aureus Adhesion and Biofilm Formation in a Rat Central Venous Catheter Model. Antimicrob Agents Chemother. 2016; 27;61(1). pii: e02020-16.
  10. Seite S, del Marmol V, Moyal D. and Friedman A. Public primary and secondary skin cancer prevention, perceptions and knowledge: An international cross-sectional survey. J Eur Acad Dermatol Venereol. 2017 Jan 3. doi: 10.1111/jdv.14104. [Epub ahead of print]
  11. Mordorski B, Costa-Orlandi C, Baltazar LM, Carreño LJ,, Landriscina A, Rosen J, Navati M, Mendes-Giannini M, Friedman JM, Nosanchuk JD, Friedman AJ. Topical nitric oxide releasing nanoparticles are effective in a murine model of dermal Trichophyton rubrum dermatophytosis. Nanomedicine. 2017 Jul 13. pii: S1549-9634(17)30127-2. doi: 10.1016/j.nano.2017.06.018. [Epub ahead of print]
  12. Austin TO, Matamoros AJ, Friedman JM, Friedman AJ, Nacharaju P, Yu W, Sharp D, Baas D. Nanoparticle Delivery of Fidgetin siRNA as a Microtubule-based Therapy to Augment Nerve Regeneration. Scientific Reports. 2017; 7, Article number: 9675.
  13. Kao S, Kiss A, Efimova T, Friedman A. An ex-vivo evaluation of cytotoxicity and melanocyte viability after A-101 hydrogen peroxide topical solution 40% or cryosurgery treatment in Seborrheic Keratosis lesions. J Am Acad Dermatol. 2018 Mar 27. pii: S0190-9622(18)30488-2. doi: 10.1016/j.jaad.2018.03.034. [Epub ahead of print]

Centers and Institutes

George Washington Institute for Nanotechnology
GW Cancer Center

Community Service

Derma Care Access Network


  • GW Cancer Center


View publications by this faculty member from January 1, 2013 - present

Additional publications published before January 1, 2013 may be available within Himmelfarb Library's database.

Industry Relationships and Collaborations

This faculty member (or a member of their immediate family) has reported a financial interest with the healthcare related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.

  • Aclaris Therapeutics
  • Allergan
  • Bayer
  • Dermira
  • Eli Lilly and Company
  • Encore Dermatology
  • Exeltis
  • Galderma
  • IntraDerm Pharmaceuticals
  • Janssen Biotech
  • Johnson and Johnson
  • La Roche-Pousay
  • Medscape
  • Menlo Therapeutics
  • Novartis
  • Pfizer
  • Regneron